Reliability and Change in Erosion Measurements by High-Resolution peripheral Quantitative Computed Tomography in a Longitudinal Dataset of Rheumatoid Arthritis Patients.

• Finzel S Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Manske SL Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Barnabe C Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Burghardt AJ Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Marotte H Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Scharmga A Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Hauge EM Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Chapurlat R Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Engelke K Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Li X Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• van Teeffelen B Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Conaghan PG Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.
• Stok KS Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany; Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, United States of America; INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France, Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France, INSERM CIE3 1408, Université de Lyon, Saint-Etienne, France; Maastricht University, Maastricht, The Netherlands; Department of Rheumatology and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark; INSERM 1033, Hôpital Edouard Herriot, 69003 Lyon Cedex, Lyon, France; Department of Biomedical Engineering, Cleveland Clinic, Cleveland, United States of America, Department of Biomedical Engineering, Melbourne School of Engineering, The University of Melbourne, Victoria 3010 Australia, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. Funding and conflicts of interest: RELEX-2 was hosted by the University of San Francisco, California, United States of America. The meeting was sponsored in part by Scanco Medical AG. PGC is supported in part by the UK National Institute for Health Research Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr. med. Stephanie Finzel, Senior Attending Physician, Head of Clinical Trials Unit Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center, Medical Faculty, University of Freiburg, Hugstetter Strasse 55, 79110 Freiburg, Germany. email: Stephanie.Finzel@uniklinik-freiburg.de.

Immunology

Immunology and Allergy

Rheumatology